



(51) International Patent Classification:

G01N 33/50 (2006.01) A61K 45/06 (2006.01)
A61K 31/337 (2006.01) C12N 5/0783 (2010.01)

(21) International Application Number:

PCT/US2024/062349

(22) International Filing Date:

30 December 2024 (30.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/616,357 29 December 2023 (29.12.2023) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton, NJ
08543 (US).

(72) Inventors: **DOWNWARD, David, Julian, Harry**; c/o The
Francis Crick Institute Limited, 1 Midland Road, London,

Greater London NW1 1AT (GB). **ANASTASIOU, Panayiotis**; c/o The Francis Crick Institute Limited, 1 Midland Road, London, Greater London NW1 1AT (GB). **COLE, Megan**; c/o The Francis Crick Institute Limited, 1 Midland Road, London, Greater London NW1 1AT (GB). **MEYER, Matthew, John**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543 (US). **VAN MALDEGEM, Febe**; c/o The Francis Crick Institute Limited, 1 Midland Road, London, Greater London NW1 1AT (GB). **WILSON, Nicholas, Stuart**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543 (US).


(74) Agent: **KIM, Ji Eun** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1101 K Street NW, 10th Floor, Washington, DC 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

(54) Title: COMBINATION THERAPY OF KRAS INHIBITOR AND TREG-DEPLETING AGENT

FIG. 29A

3LL orthotopic model - survival experiment



(57) Abstract: In some aspects, the present disclosure is directed to a method of treating a tumor in a subject in need thereof comprising administering a KRAS inhibitor and a regulatory T cell (Treg)-depleting agent to the subject. In some aspects, the present disclosure is further directed to methods of reducing the number of Treg cells (Tregs) in a tumor environment (TME) in a subject who receives a therapy with a KRAS inhibitor comprising administering a Treg-depleting agent to the subject. In some aspects, the present disclosure is further directed to methods of treating a tumor in a subject who is identified as having an increased number of Tregs in a TME, or as having a spatial cellular community comprising Tregs in a TME.

[Continued on next page]

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))